In Ph-B-ALL, patients with IKZF1 or CDKN2A/B deletion showed poor prognosis; allo-HSCT could improve the OS in patients with IKZF1 deletion but could not improve the OS in patients with CDKN2A/B deletion. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.